Novel ANP-Based Therapy for Hypertension
Insufficient control of blood pressure (BP) in hypertension continues to represent an unmet need of contemporary medicine. In a recent analysis performed by the NCD-RisC (non-communicable diseases Risk Factor Collaboration), BP control ranged from about 15% to 60%.1 In addition, a cross-sectional analysis of National Health and Nutrition Examination Survey showed that the proportion of patients with controlled BP has even declined to 43.7% in the most recent timeframe (2017–2018).2
